This is a preprint.
Respiratory Infection- and Asthma-prone, Low Vaccine Responder Children Demonstrate Distinct Mononuclear Cell DNA Methylation Pathways
- PMID: 38645021
- PMCID: PMC11030504
- DOI: 10.21203/rs.3.rs-4160354/v1
Respiratory Infection- and Asthma-prone, Low Vaccine Responder Children Demonstrate Distinct Mononuclear Cell DNA Methylation Pathways
Update in
-
Respiratory infection- and asthma-prone, low vaccine responder children demonstrate distinct mononuclear cell DNA methylation pathways.Clin Epigenetics. 2024 Jul 3;16(1):85. doi: 10.1186/s13148-024-01703-0. Clin Epigenetics. 2024. PMID: 38961479 Free PMC article.
Abstract
Background: Infants with frequent viral and bacterial respiratory infections exhibit compromised immunity to routine immunisations. They are also more likely to develop chronic respiratory diseases in later childhood. This study investigated the feasibility of epigenetic profiling to reveal endotype-specific molecular pathways with potential for early identification and immuno-modulation. Peripharal immune cells from respiratory infection allergy/asthma prone (IAP) infants were retrospectively selected for genome-wide DNA methylation and single nucleotide polymorphism analysis. The IAP infants were enriched for the low vaccine responsiveness (LVR) phenotype (Fishers Exact p-value = 0.01).
Results: An endotype signature of 813 differentially methylated regions (DMRs) comprising 238 lead CpG associations (FDR < 0.05) emerged, implicating pathways related to asthma, mucin production, antigen presentation and inflammasome activation. Allelic variation explained only a minor portion of this signature. Stimulation of mononuclear cells with monophosphoryl lipid A (MPLA), a TLR agonist, partially reversing this signature at a subset of CpGs, suggesting the potential for epigenetic remodelling.
Conclusions: This proof-of-concept study establishes a foundation for precision endotyping of IAP children and highlights the potential for immune modulation strategies using adjuvants for furture investigation.
Conflict of interest statement
Competing interests JL-S is a scientific advisor to Precion Inc. and TruDiagnostic Inc. OL and SvH are named inventors on patents related to vaccine adjuvants and human in vitro systems that model immune responses. Their laboratories have received a sponsored research agreement from GlaxoSmithKline (GSK). OL is a co-founder of Ovax LLC.
Figures
References
-
- WHO. Neonatal Mortality Rate (SDG 3.2.2). In: The Global Strategy for Women’s, Children’s and Adolescents’ Health (2016–2030). 2015.
-
- Pichichero ME. Ten-Year Study of Acute Otitis Media in Rochester, NY. Pediatr Infect Dis J. 2016;35(9):1027–32. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
